ProCE Banner Activity

Biomarker Testing in Prostate Cancer: An Educational Program for Pathologists and Medical Oncologists

Clinical Thought

In this commentary, get a tour of an online educational program designed by pathology and medical oncology experts on optimal biomarker testing in prostate cancer to guide treatment decisions for advanced disease.

Released: April 11, 2024

Expiration: April 10, 2025

Share

Faculty

Himisha Beltran

Himisha Beltran, MD

Associate Professor of Medicine
Department of Medical Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts 

Steven Christopher Smith

Steven Christopher Smith, MD, PhD

Associate Professor of Pathology and Surgery
Director, Genitourinary and Soft Tissue Pathology
VCU School of Medicine and Massey Comprehensive Cancer Center
Richmond, Virginia

Provided by

Provided by Clinical Care Options, LLC in partnership with the American Society for Clinical Pathology

ProCE Banner

Supporters

Supported by an educational grant from Pfizer, Inc.

Pfizer, Inc.

Partners

American Society for Clinical Pathology

ProCE Banner

Disclosure

Primary Author

Himisha Beltran, MD

Associate Professor of Medicine
Department of Medical Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts 

Himisha Beltran, MD: consultant/advisor/speaker: Amgen, Bayer, Janssen, Merck, Pfizer, Roche; researcher: Bristol Myers Squibb, Circle Pharma, Daiichi Sankyo, Novartis.

Steven Christopher Smith, MD, PhD

Associate Professor of Pathology and Surgery
Director, Genitourinary and Soft Tissue Pathology
VCU School of Medicine and Massey Comprehensive Cancer Center
Richmond, Virginia

Steven Christopher Smith, MD, PhD, has no relevant financial relationships to disclose.